Financial Comparison: Viridian Therapeutics (NASDAQ:VRDN) & Exicure (NASDAQ:XCUR)

Exicure (NASDAQ:XCUR – Get Free Report) and Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation.

Volatility and Risk

Exicure has a beta of 3.83, indicating that its stock price is 283% more volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.

Profitability

This table compares Exicure and Viridian Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Exicure N/A -237.91% -61.98%
Viridian Therapeutics -1,620.79% -79.67% -44.72%

Institutional and Insider Ownership

42.8% of Exicure shares are owned by institutional investors. 52.8% of Exicure shares are owned by company insiders. Comparatively, 2.4% of Viridian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Exicure and Viridian Therapeutics”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Exicure N/A N/A -$4.95 million ($0.83) -1.08
Viridian Therapeutics $26.31 million 129.32 -$342.60 million ($3.84) -7.80

Exicure has higher earnings, but lower revenue than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Exicure and Viridian Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exicure 1 0 0 0 1.00
Viridian Therapeutics 1 0 12 0 2.85

Viridian Therapeutics has a consensus target price of $41.46, indicating a potential upside of 38.39%. Given Viridian Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Viridian Therapeutics is more favorable than Exicure.

Summary

Exicure beats Viridian Therapeutics on 7 of the 13 factors compared between the two stocks.

About Exicure

(Get Free Report)

Exicure, Inc. is a biotechnology company historically focused on developing nucleic acid-based therapeutics. Its research has centered on spherical nucleic acid (SNA) technology, a platform designed to deliver genetic material into cells and influence disease-related gene activity. The company has pursued potential treatments for conditions including rare genetic disorders and cancer. Its work has included research into therapies intended to address diseases with limited treatment options. Exicure was based in Chicago, Illinois.

About Viridian Therapeutics

(Get Free Report)

Viridian Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a primary focus on thyroid eye disease (TED), an autoimmune condition that can cause inflammation and changes around the eyes. The company’s pipeline includes veligrotug, an investigational antibody that targets the insulin-like growth factor 1 receptor, a pathway involved in TED. Viridian is also developing additional antibody-based candidates intended to offer treatment options, including formulations designed for under-the-skin administration.

Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.